[96a5a0]: / output / allTrials / logical / NCT02364531_logical.json

Download this file

628 lines (628 with data), 30.0 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
{
"info": {
"nct_id": "NCT02364531",
"official_title": "A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting. The COSMiC Prospective Prostate Cancer Registry",
"inclusion_criteria": "* Participants must have a confirmed diagnosis of metastatic castrate-resistant prostate cancer (mCRPC) according to medical history and have rising Prostate-Specific Antigen (PSA) levels or radiographic progression (documented by previous positive bone scan or metastatic lesions identified on CT or MRI) despite ongoing conventional Androgen deprivation therapy (ADT)\n* Participant (or legally accepted representative) must be able to sign an informed consent form (ICF) indicating that they understand the procedures for data collection and are willing to participate in the study\n* Participant must be able to understand and complete study questionnaires\n* Abiraterone Acetate (ZYTIGA) has been chosen as the treatment for mCRPC disease progression as part of standard of care\n* Male participants aged greater than (>) 18 years\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Participants currently participating in another investigational clinical study of ZYTIGA or any other investigational drug\n* Participants who have received prior cytotoxic chemotherapy for prostate cancer while receiving ADT\n* Participants who have any other condition that, in the opinion of the investigator, may affect the participants health or outcome of the trial (i.e. uncontrolled disease)\n* Life expectancy of less than (<) 1 year\n* History of another malignancy within the previous 5 years other than curatively treated non-melanoma skin cancer",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Participants must have a confirmed diagnosis of metastatic castrate-resistant prostate cancer (mCRPC) according to medical history and have rising Prostate-Specific Antigen (PSA) levels or radiographic progression (documented by previous positive bone scan or metastatic lesions identified on CT or MRI) despite ongoing conventional Androgen deprivation therapy (ADT)",
"criterions": [
{
"exact_snippets": "confirmed diagnosis of metastatic castrate-resistant prostate cancer (mCRPC)",
"criterion": "diagnosis",
"requirement": {
"requirement_type": "presence",
"expected_value": "metastatic castrate-resistant prostate cancer (mCRPC)"
}
},
{
"exact_snippets": "rising Prostate-Specific Antigen (PSA) levels",
"criterion": "Prostate-Specific Antigen (PSA) levels",
"requirement": {
"requirement_type": "trend",
"expected_value": "rising"
}
},
{
"exact_snippets": "radiographic progression (documented by previous positive bone scan or metastatic lesions identified on CT or MRI)",
"criterion": "radiographic progression",
"requirement": {
"requirement_type": "documentation",
"expected_value": [
"previous positive bone scan",
"metastatic lesions identified on CT",
"metastatic lesions identified on MRI"
]
}
},
{
"exact_snippets": "ongoing conventional Androgen deprivation therapy (ADT)",
"criterion": "Androgen deprivation therapy (ADT)",
"requirement": {
"requirement_type": "status",
"expected_value": "ongoing"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "confirmed diagnosis of metastatic castrate-resistant prostate cancer (mCRPC)",
"criterion": "diagnosis",
"requirement": {
"requirement_type": "presence",
"expected_value": "metastatic castrate-resistant prostate cancer (mCRPC)"
}
},
{
"exact_snippets": "ongoing conventional Androgen deprivation therapy (ADT)",
"criterion": "Androgen deprivation therapy (ADT)",
"requirement": {
"requirement_type": "status",
"expected_value": "ongoing"
}
},
{
"or_criteria": [
{
"exact_snippets": "rising Prostate-Specific Antigen (PSA) levels",
"criterion": "Prostate-Specific Antigen (PSA) levels",
"requirement": {
"requirement_type": "trend",
"expected_value": "rising"
}
},
{
"exact_snippets": "radiographic progression (documented by previous positive bone scan or metastatic lesions identified on CT or MRI)",
"criterion": "radiographic progression",
"requirement": {
"requirement_type": "documentation",
"expected_value": [
"previous positive bone scan",
"metastatic lesions identified on CT",
"metastatic lesions identified on MRI"
]
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* Participant (or legally accepted representative) must be able to sign an informed consent form (ICF) indicating that they understand the procedures for data collection and are willing to participate in the study",
"criterions": [
{
"exact_snippets": "Participant (or legally accepted representative) must be able to sign an informed consent form (ICF)",
"criterion": "ability to sign informed consent form",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
},
{
"exact_snippets": "indicating that they understand the procedures for data collection",
"criterion": "understanding of data collection procedures",
"requirement": {
"requirement_type": "understanding",
"expected_value": true
}
},
{
"exact_snippets": "willing to participate in the study",
"criterion": "willingness to participate",
"requirement": {
"requirement_type": "willingness",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Participant (or legally accepted representative) must be able to sign an informed consent form (ICF)",
"criterion": "ability to sign informed consent form",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
},
{
"exact_snippets": "indicating that they understand the procedures for data collection",
"criterion": "understanding of data collection procedures",
"requirement": {
"requirement_type": "understanding",
"expected_value": true
}
},
{
"exact_snippets": "willing to participate in the study",
"criterion": "willingness to participate",
"requirement": {
"requirement_type": "willingness",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Participant must be able to understand and complete study questionnaires",
"criterions": [
{
"exact_snippets": "Participant must be able to understand",
"criterion": "cognitive ability",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
},
{
"exact_snippets": "complete study questionnaires",
"criterion": "ability to complete questionnaires",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Participant must be able to understand",
"criterion": "cognitive ability",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
},
{
"exact_snippets": "complete study questionnaires",
"criterion": "ability to complete questionnaires",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Abiraterone Acetate (ZYTIGA) has been chosen as the treatment for mCRPC disease progression as part of standard of care",
"criterions": [
{
"exact_snippets": "Abiraterone Acetate (ZYTIGA) has been chosen as the treatment",
"criterion": "treatment choice",
"requirement": {
"requirement_type": "expected treatment",
"expected_value": "Abiraterone Acetate (ZYTIGA)"
}
},
{
"exact_snippets": "mCRPC disease progression",
"criterion": "disease progression",
"requirement": {
"requirement_type": "condition",
"expected_value": "mCRPC"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Abiraterone Acetate (ZYTIGA) has been chosen as the treatment",
"criterion": "treatment choice",
"requirement": {
"requirement_type": "expected treatment",
"expected_value": "Abiraterone Acetate (ZYTIGA)"
}
},
{
"exact_snippets": "mCRPC disease progression",
"criterion": "disease progression",
"requirement": {
"requirement_type": "condition",
"expected_value": "mCRPC"
}
}
]
}
},
{
"identified_line": {
"line": "* Male participants aged greater than (>) 18 years",
"criterions": [
{
"exact_snippets": "Male participants",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "male"
}
},
{
"exact_snippets": "aged greater than (>) 18 years",
"criterion": "age",
"requirement": {
"requirement_type": "comparison",
"expected_value": {
"operator": ">",
"value": 18,
"unit": "years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Male participants",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "male"
}
},
{
"exact_snippets": "aged greater than (>) 18 years",
"criterion": "age",
"requirement": {
"requirement_type": "comparison",
"expected_value": {
"operator": ">",
"value": 18,
"unit": "years"
}
}
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "Must be MALE",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "male"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Must be MALE",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "male"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* Participants currently participating in another investigational clinical study of ZYTIGA or any other investigational drug",
"criterions": [
{
"exact_snippets": "Participants currently participating in another investigational clinical study of ZYTIGA",
"criterion": "participation in investigational clinical study of ZYTIGA",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Participants currently participating in ... any other investigational drug",
"criterion": "participation in investigational clinical study of any other investigational drug",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Participants currently participating in another investigational clinical study of ZYTIGA",
"criterion": "participation in investigational clinical study of ZYTIGA",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Participants currently participating in ... any other investigational drug",
"criterion": "participation in investigational clinical study of any other investigational drug",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Participants who have received prior cytotoxic chemotherapy for prostate cancer while receiving ADT",
"criterions": [
{
"exact_snippets": "Participants who have received prior cytotoxic chemotherapy for prostate cancer",
"criterion": "prior cytotoxic chemotherapy for prostate cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "while receiving ADT",
"criterion": "ADT",
"requirement": {
"requirement_type": "concurrent treatment",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Participants who have received prior cytotoxic chemotherapy for prostate cancer",
"criterion": "prior cytotoxic chemotherapy for prostate cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "while receiving ADT",
"criterion": "ADT",
"requirement": {
"requirement_type": "concurrent treatment",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Participants who have any other condition that, in the opinion of the investigator, may affect the participants health or outcome of the trial (i.e. uncontrolled disease)",
"criterions": [
{
"exact_snippets": "any other condition ... may affect the participants health or outcome of the trial",
"criterion": "other condition",
"requirement": {
"requirement_type": "impact",
"expected_value": "may affect health or outcome of the trial"
}
},
{
"exact_snippets": "uncontrolled disease",
"criterion": "disease control",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "any other condition ... may affect the participants health or outcome of the trial",
"criterion": "other condition",
"requirement": {
"requirement_type": "impact",
"expected_value": "may affect health or outcome of the trial"
}
},
{
"exact_snippets": "uncontrolled disease",
"criterion": "disease control",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Life expectancy of less than (<) 1 year",
"criterions": [
{
"exact_snippets": "Life expectancy of less than (<) 1 year",
"criterion": "life expectancy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<",
"value": 1,
"unit": "year"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Life expectancy of less than (<) 1 year",
"criterion": "life expectancy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<",
"value": 1,
"unit": "year"
}
}
}
]
}
},
{
"identified_line": {
"line": "* History of another malignancy within the previous 5 years other than curatively treated non-melanoma skin cancer",
"criterions": [
{
"exact_snippets": "History of another malignancy within the previous 5 years",
"criterion": "history of another malignancy",
"requirement": {
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 5,
"unit": "years"
}
]
}
}
},
{
"exact_snippets": "other than curatively treated non-melanoma skin cancer",
"criterion": "curatively treated non-melanoma skin cancer",
"requirement": {
"requirement_type": "exclusion",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"not_criteria": {
"and_criteria": [
{
"exact_snippets": "History of another malignancy within the previous 5 years",
"criterion": "history of another malignancy",
"requirement": {
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 5,
"unit": "years"
}
]
}
}
},
{
"not_criteria": {
"exact_snippets": "other than curatively treated non-melanoma skin cancer",
"criterion": "curatively treated non-melanoma skin cancer",
"requirement": {
"requirement_type": "exclusion",
"expected_value": true
}
}
}
]
}
}
]
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}